Dr. Ziegelmann on Peyronie's disease: “Collagenase remains a very important treatment option”

"While our results may imply that a strict all-business professionalism is superior, I think it's important to acknowledge that humor is really subjective," says Max D. Sandler.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

"I think all the major implant companies are constantly improving the devices," says Hossein Sadeghi-Nejad, MD, FACS.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

“Over the 4-year period since first-line protocol therapy initiation, [patients treated with] nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib," says Charlene Mantia, MD.

“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.